SLCO1B1

Solute carrier organic anion transporter family member 1B1 · Q9Y6L6 · SLCO1B1 on Sugi Atlas →

117,572 patent compounds predicted against SLCO1B1, 91,734 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Pravastatin (SCHEMBL1117)	1.00	4/20
Atorvastatin (SCHEMBL3831)	1.00	4/20
SCHEMBL1032	0.81	4/20
SCHEMBL9906	0.72	4/20
SCHEMBL1290	0.69	4/20
SCHEMBL1444	0.50	4/20
Simvastatin (SCHEMBL2471)	1.00	3/20
Simvastatin (SCHEMBL2472)	1.00	3/20
Erythromycin Propionate (SCHEMBL3331)	1.00	3/20
Atorvastatin (SCHEMBL3832)	1.00	3/20
Erythromycin Ethylsuccinate (SCHEMBL18259)	1.00	3/20
Pravastatin (SCHEMBL3013)	0.84	3/20
Pravastatin (SCHEMBL3014)	0.84	3/20
Atorvastatin Lactone (SCHEMBL1265)	1.00	2/20
Atorvastatin Lactone (SCHEMBL1266)	1.00	2/20
Rifamycin (SCHEMBL2320)	1.00	2/20
Lovastatin (SCHEMBL3136)	1.00	2/20
Lovastatin (SCHEMBL3137)	1.00	2/20
Vinblastine (SCHEMBL3628)	1.00	2/20
Vinblastine (SCHEMBL3629)	1.00	2/20

Clinical trials — most relevant to SLCO1B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
The Interaction of Herbs and Statins	PHASE4	COMPLETED
Drug Transporter Interaction Study PHENTRA_2015_KPUK	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Confirmatory Study of Govorestat in CMT-SORD	PHASE3	WITHDRAWN
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer	PHASE2	COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	PHASE1	RECRUITING
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study	EARLY_PHASE1	NOT_YET_RECRUITING
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
Integrating Pharmacogenetics In Clinical Care	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a SLCO1B1 binder may also engage these)

Protein	Name	Similarity
Q9QZX8	—	1.000	Q9QZX8 →
F5H094	—	1.000	F5H094 →
SLCO1B3	Solute carrier organic anion transporter family member 1B3	1.000	landscape →
Q9JJL3	—	1.000	Q9JJL3 →
P46720	—	0.999	P46720 →
Q9ERB5	—	0.998	Q9ERB5 →
Q9GMU6	—	0.997	Q9GMU6 →
SLCO1A2	Solute carrier organic anion transporter family member 1A2	0.996	landscape →
G3V0H7	—	0.995	G3V0H7 →
Q99J94	—	0.995	Q99J94 →
Q9NYB5	—	0.995	Q9NYB5 →
Q9QYE2	—	0.994	Q9QYE2 →
Q5RFF0	—	0.992	Q5RFF0 →
Q9EP96	—	0.991	Q9EP96 →
P70502	—	0.991	P70502 →
Q9UIG8	—	0.991	Q9UIG8 →
SLCO4C1	Solute carrier organic anion transporter family member 4C1	0.991	landscape →
Q91YY5	—	0.991	Q91YY5 →
Q9VVH9	—	0.991	Q9VVH9 →
Q9EPZ7	—	0.990	Q9EPZ7 →
Q9QXZ6	—	0.990	Q9QXZ6 →
Q8BGD4	—	0.988	Q8BGD4 →
Q71MB6	—	0.988	Q71MB6 →
O35913	—	0.988	O35913 →
O88397	—	0.986	O88397 →
A1Z7R6	—	0.986	A1Z7R6 →
Q3EAQ5	—	0.986	Q3EAQ5 →
Q8C0X7	—	0.985	Q8C0X7 →
Q17758	—	0.984	Q17758 →
Q7Z118	—	0.984	Q7Z118 →